These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34367648)

  • 21. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care.
    Bohorquez H; Bugeaud E; Bzowej N; Scheuermann J; Hand J; Bruce D; Carmody I; Cohen A; Joshi S; Seal J; Sonnier D; Therapondos G; Girgrah N; Anders S; Loss GE
    Liver Transpl; 2021 Apr; 27(4):548-557. PubMed ID: 33098277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updated View on Kidney Transplant from HCV-Infected Donors and DAAs.
    Fabrizi F; Cerutti R; Alfieri CM; Messa P
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
    Cannon RM; Locke JE; Orandi BJ; Anderson DJ; Davis EG; Mackelaite L; Dave H; Eng M; Jones CM
    Transplantation; 2020 Jun; 104(6):1215-1228. PubMed ID: 31517783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era.
    Madan S; Patel SR; Rahgozar K; Saeed O; Murthy S; Vukelic S; Sims DB; Shin JJ; Goldstein DJ; Jorde UP
    J Heart Lung Transplant; 2019 Sep; 38(9):907-917. PubMed ID: 31495408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.
    Reyentovich A; Gidea CG; Smith D; Lonze B; Kon Z; Fargnoli A; Pavone J; Rao S; Saraon T; Lewis T; Qian Y; Jacobson I; Moazami N
    Clin Transplant; 2020 Sep; 34(9):e13989. PubMed ID: 32441413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era.
    Kapila N; Al-Khalloufi K; Bejarano PA; Vanatta JM; Zervos XB
    Am J Transplant; 2020 Feb; 20(2):600-605. PubMed ID: 31448549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Best practice recommendations for the use of hepatitis C viremic donor organs for hepatitis C virus naïve recipients.
    Stewart ZA; Shah SA; Rolls JA; Guarrera JV; Kandaswamy R; Axelrod DA
    Clin Transplant; 2021 Aug; 35(8):e14381. PubMed ID: 34086371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of hepatitis C virus-positive donors in kidney transplantation.
    Shetty A; Ariyamuthu VK; Gungor AB; Tanriover B
    Curr Opin Organ Transplant; 2023 Feb; 28(1):22-28. PubMed ID: 36227758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes of heart transplantation using hepatitis c-viremic donors: A systematic review with meta-analysis.
    Villegas-Galaviz J; Anderson E; Guglin M
    J Heart Lung Transplant; 2022 Apr; 41(4):538-549. PubMed ID: 35153130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Results of Pilot Study Using Hepatitis C Virus (HCV) Positive Kidneys to Transplant HCV Infected Patients with End-Stage Renal Disease Allowing for Successful Interferon-Free Direct Acting Antiviral Therapy after Transplantation.
    Gallegos-Orozco JF; Kim R; Thiesset HF; Hatch J; Lynch K; Chaly T; Shihab F; Ahmed F; Hall I; Campsen J
    Cureus; 2016 Nov; 8(11):e890. PubMed ID: 28018760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients.
    Duerr M; Liefeldt L; Friedersdorff F; Choi M; Öllinger R; Hofmann J; Budde K; Schrezenmeier E; Halleck F
    J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33383877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy.
    Kapila N; Khalloufi KA; Flocco G; Menon KVN; Lindenmeyer C; Reino D; Vanatta JM; Ebaid S; Tzakis A; Zervos XB
    J Clin Transl Hepatol; 2019 Jun; 7(2):122-126. PubMed ID: 31293911
    [No Abstract]   [Full Text] [Related]  

  • 34. A real-world, single-center experience of the utilization of hepatitis C-viremic kidneys for hepatitis C-negative recipients.
    Daloul R; Anthony M; Washburn K; Singh P; Pesavento T
    Clin Nephrol; 2021 Oct; 96(4):216-225. PubMed ID: 34169833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of Kidneys Transplanted From Hepatitis C Viremic Donors to Naive Recipients From an Appalachian Rural Kidney Transplant Program.
    Gillis B; Villanueva D; Marsh W; Afridi F; Danforth J; Thornberg M; Chaudhary V; Sharma R
    Exp Clin Transplant; 2024 Mar; 22(3):185-188. PubMed ID: 38695587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report.
    Said A; Weiss M; Varhelyi A; Farago R; Ballweg C; Rice J; Agarwal P; Fernandez L; Foley D
    Transpl Infect Dis; 2021 Apr; 23(2):e13466. PubMed ID: 32931616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post-transplant viremia.
    Khan S; Mazumder R; Wang X; Wang Y; Sims OT; Budev M; Carey W
    Clin Transplant; 2024 May; 38(5):e15325. PubMed ID: 38716770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning.
    Bethea E; Arvind A; Gustafson J; Andersson K; Pratt D; Bhan I; Thiim M; Corey K; Bloom P; Markmann J; Yeh H; Elias N; Kimura S; Dageforde LA; Cuenca A; Kawai T; Safa K; Williams W; Gilligan H; Sise M; Fishman J; Kotton C; Kim A; Rogers CC; Shao S; Cote M; Irwin L; Myoung P; Chung RT
    Am J Transplant; 2020 Jun; 20(6):1619-1628. PubMed ID: 31887236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool.
    Keller J; Marklin G; Okoye O; Desai R; Sura T; Jain A; Varma C; Nazzal M
    J Transplant; 2021; 2021():6612453. PubMed ID: 33564467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplant of a Kidney from a Hepatitis C Viremic Donor to a Naïve Recipient without Viral Transmission: A Case Report.
    Rawashdeh B; Hulse J; Agarwal A
    Am J Case Rep; 2021 May; 22():e927532. PubMed ID: 33953151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.